Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|March 2, 2020
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancerMichael Overman, Milind Javle, Richard E Davis, et al.
World Journal for Pediatric & Congenital Heart Surgery|September 10, 2019
Impact of 3D Printouts in Optimizing Surgical Results for Complex Congenital Heart DiseaseFrank Han, Jennifer Co-Vu, Dalia Lopez-Colon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept StudyMatthew H Taylor, Courtney B Betts, Lauren Maloney, et al.
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyToby A Eyre, Anna Schuh, William G Wierda, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
Echocardiography (Mount Kisco, N.Y.)|October 2, 2019
The case of the missing pulmonary vein: A focused update on anomalous pulmonary venous connection in congenital cardiovascular diseaseFrank Han, Sara Kiparizoska, William Campbell, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
Blood|March 31, 2021
Acalabrutinib in treatment-naive chronic lymphocytic leukemiaJohn C Byrd, Jennifer A Woyach, Richard R Furman, et al.
Blood Advances|May 16, 2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinibFarrukh T Awan, Anna Schuh, Jennifer R Brown, et al.
Pageof 8